{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:10:06Z","timestamp":1743379806907,"version":"3.40.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,30]]},"DOI":"10.7759\/cureus.81474","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:55:24Z","timestamp":1743378924000},"source":"Crossref","is-referenced-by-count":0,"title":["Combination Treatment With Intravenous and Oral Calcimimetics for Secondary Hyperparathyroidism in Hemodialysis Patients Who Decline Parathyroidectomy"],"prefix":"10.7759","author":[{"given":"Ryoichi","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Onozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakanobu","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow GM","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012, 367:2482-94. 10.1056\/NEJMoa1205624","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010020186","article-title":"The regulation of parathyroid hormone secretion and synthesis","volume":"22","author":"Kumar R","year":"2011","unstructured":"Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011, 22:216-24. 10.1681\/ASN.2010020186","journal-title":"J Am Soc Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn191","article-title":"Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet","volume":"23","author":"de Francisco AL","year":"2008","unstructured":"de Francisco AL, Izquierdo M, Cunningham J, et al.. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant. 2008, 23:2895-901. 10.1093\/ndt\/gfn191","journal-title":"Nephrol Dial Transplant"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.13662","article-title":"Structural mechanism of ligand activation in human calcium-sensing receptor","volume":"5","author":"Geng Y","year":"2016","unstructured":"Geng Y, Mosyak L, Kurinov I, et al.. Structural mechanism of ligand activation in human calcium-sensing receptor. Elife. 2016, 5:10.7554\/eLife.13662","journal-title":"Elife"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block GA","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, et al.. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017, 317:156-64. 10.1001\/jama.2016.19468","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa M","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018, 94:818-25. 10.1016\/j.kint.2018.05.013","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa M","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, et al.. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013, 17:247-88. 10.1111\/1744-9987.12058","journal-title":"Ther Apher Dial"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism","volume":"5","author":"Komaba H","year":"2010","unstructured":"Komaba H, Nakanishi S, Fujimori A, et al.. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010, 5:2305-14. 10.2215\/CJN.02110310","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12352","article-title":"Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the Parathyroid Surgeons' Society of Japan","volume":"20","author":"Tominaga Y","year":"2016","unstructured":"Tominaga Y, Kakuta T, Yasunaga C, Nakamura M, Kadokura Y, Tahara H. Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the Parathyroid Surgeons' Society of Japan. Ther Apher Dial. 2016, 20:6-11. 10.1111\/1744-9987.12352","journal-title":"Ther Apher Dial"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1169793","article-title":"Treatment for secondary hyperparathyroidism focusing on parathyroidectomy","volume":"14","author":"Hiramitsu T","year":"2023","unstructured":"Hiramitsu T, Hasegawa Y, Futamura K, et al.. Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Front Endocrinol (Lausanne). 2023, 14:10.3389\/fendo.2023.1169793","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter S","year":"2013","unstructured":"Walter S, Baruch A, Dong J, et al.. Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013, 346:229-40. 10.1124\/jpet.113.204834","journal-title":"J Pharmacol Exp Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.122.000522","article-title":"Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor","volume":"102","author":"Sato H","year":"2022","unstructured":"Sato H, Murakami S, Horii Y, Nishimura G, Iwai R, Goto M, Takahashi N. Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor. Mol Pharmacol. 2022, 102:183-95. 10.1124\/molpharm.122.000522","journal-title":"Mol Pharmacol"},{"key":"ref13","unstructured":"The 67th Annual Meeting Japanese Society of Nephrology. (2024). https.\/\/jsn.or.jp\/general\/congress\/journal\/66_4.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009","volume":"65","author":"Butler AM","year":"2015","unstructured":"Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, Brookhart MA. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009. Am J Kidney Dis. 2015, 65:763-72. 10.1053\/j.ajkd.2014.12.013","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00819.x","article-title":"Long-term natural history of acquired cystic disease of the kidney","volume":"14","author":"Ishikawa I","year":"2010","unstructured":"Ishikawa I, Hayama S, Morita K, et al.. Long-term natural history of acquired cystic disease of the kidney. Ther Apher Dial. 2010, 14:409-16. 10.1111\/j.1744-9987.2010.00819.x","journal-title":"Ther Apher Dial"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad213","article-title":"Hypocalcemia and cardiovascular mortality in cinacalcet users","volume":"39","author":"Goto S","year":"2024","unstructured":"Goto S, Hamano T, Fujii H, Taniguchi M, Abe M, Nitta K, Nishi S. Hypocalcemia and cardiovascular mortality in cinacalcet users. Nephrol Dial Transplant. 2024, 39:637-47. 10.1093\/ndt\/gfad213","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac142","article-title":"Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis","volume":"107","author":"Komaba H","year":"2022","unstructured":"Komaba H, Hamano T, Fujii N, et al.. Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocrinol Metab. 2022, 107:2016-25. 10.1210\/clinem\/dgac142","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332192-combination-treatment-with-intravenous-and-oral-calcimimetics-for-secondary-hyperparathyroidism-in-hemodialysis-patients-who-decline-parathyroidectomy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:55:26Z","timestamp":1743378926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332192-combination-treatment-with-intravenous-and-oral-calcimimetics-for-secondary-hyperparathyroidism-in-hemodialysis-patients-who-decline-parathyroidectomy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.81474","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}